NCT00136474View on ClinicalTrials.gov

Amifostine for Head and Neck Irradiation in Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

May 31, 2005

Study Completion Date

March 31, 2009

Conditions
LymphomaHodgkin's DiseaseNon-Hodgkin's Lymphoma
Interventions
DRUG

Amifostine

Given 30-60 minutes prior to daily radiation therapy

RADIATION

Radiation Therapy

Daily radiation therapy

Trial Locations (2)

02115

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

MedImmune LLC
All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

MedImmune LLC

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER